RxDoctor Payments Data

Stephen Caso, PA

Physician Assistant · Temecula, CANPI 1083916985

Payments from drug & device makers

$13,098in general payments, 2019–2025

Across 548 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • GSK$855
  • AstraZeneca$809
  • Lilly USA, LLC$790
  • Gilead$723
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,084100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,098 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$182,583
Medicare patients
234
Services billed
4,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$80,184
EliquisApixaban78$72,159
FarxigaDapagliflozin Propanediol50$53,610
JardianceEmpagliflozin38$51,387
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$45,555
TrulicityDulaglutide31$44,266
XareltoRivaroxaban39$35,883
EntrestoSacubitril/Valsartan13$23,764
JanuviaSitagliptin Phosphate14$21,841
Victoza 3-PakLiraglutide11$13,615
Repatha SureclickEvolocumab14$11,837
Breo ElliptaFluticasone/Vilanterol15$11,430
MyrbetriqMirabegron13$11,018
TradjentaLinagliptin12$9,674
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$523$80,18458 claims
PfizerEliquis$334$72,15978 claims
Boehringer IngelheimJardiance, Tradjenta$207$61,06150 claims
AstraZenecaFarxiga, Breztri Aerosphere$809$60,66361 claims
GSKTrelegy Ellipta, Breo Ellipta$855$56,98571 claims
Lilly USA, LLCTrulicity, Humalog$790$46,87053 claims
Johnson & JohnsonXarelto$65$35,88339 claims
NovartisEntresto$590$23,76413 claims
MerckJanuvia$117$21,84114 claims
Arbor Pharmaceuticals, Inc.Edarbi$35$5,28415 claims
AbbVieSynthroid$1,540$4,36452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →